Current status of pharmacotherapy for primary sclerosing cholangitis
Primary sclerosing cholangitis (PSC) represents a cholestatic disease hallmarked by persistent and progressive inflammation of the bile ducts. Despite its low incidence and unfavorable prognosis, there is no pharmacological therapy capable of altering the course of PSC, and liver transplantation is...
Saved in:
Main Authors: | Hang Yang, Juan Zhen, Xiaoyan Huang, Minqi Chen, Hongsi Cui, Xia Sheng, Xinyu Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-06-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1544601/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PREGNANCY WITH PRIMARY SCLEROSING CHOLANGITIS
by: E. A. Alexandrova, et al.
Published: (2016-09-01) -
Overlap syndrome of seronegative primary biliary cholangitis and small duct primary sclerosing cholangitis: a first case report and literature review
by: Salma Souissi, et al.
Published: (2024-12-01) -
Prognostic Models of Primary Sclerosing Cholangitis
by: A. I. Dolgushina, et al.
Published: (2023-02-01) -
Recurrence of primary sclerosing cholangitis in the graft
by: E. S. Pak, et al.
Published: (2024-09-01) -
Clinical Features, Differential Diagnosis and Treatment of IgG<sub>4</sub>-Related Sclerosing Cholangitis
by: A. K. Guseva, et al.
Published: (2024-04-01)